You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed AML

Showing 51 - 75 of 6,742
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

NHL, Adult, AML, Adult Recurrent Trial in Zhengzhou, Tianjin (ETH-155008)

Recruiting
  • NHL, Adult
  • AML, Adult Recurrent
  • Zhengzhou, Henan, China
  • +1 more
Feb 24, 2023

Acute Myeloid Leukaemia Trial (SAR445419, fludarabine, cytarabine)

Not yet recruiting
  • Acute Myeloid Leukaemia
  • (no location specified)
Feb 2, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial (LILRB4 STAR-T cells)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • LILRB4 STAR-T cells
  • (no location specified)
Sep 16, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Trial in Zhengzhou (6MW3211

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • 6MW3211 injection with Intravenous Infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 2, 2022

Immunobiology of Acute Myeloid Leukemia Relapses After

Recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Observations on Relapsed AML Allogeneic Transplanted patients
  • Milan, Milano, Italy
    IRCCS Ospedale San Raffaele
Jul 18, 2022

Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)

Not yet recruiting
  • Leukemia, Acute Myeloid (AML)
  • (no location specified)
Oct 16, 2022

AML Trial in Hangzhou (ADGRE2 CAR-T)

Not yet recruiting
  • AML
  • ADGRE2 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 17, 2022

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)

Suspended
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Tampa, Florida
    Moffitt Cancer Center
Nov 11, 2022

Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Seattle (SC-DARIC33)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • SC-DARIC33
  • Seattle, Washington
    Seattle Children's Hospital
Sep 6, 2022

Acute Myeloid Leukemia Trial in Stanford (Talazoparib, Topotecan, Gemcitabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Stanford, California
    Stanford University
Jun 10, 2022

AML, Adult Trial in Tianjin (QN-023a, Cyclophosphamid, Fludarabine)

Recruiting
  • AML, Adult
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 3, 2022

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, MDS Trial (biological, drug, procedure)

Withdrawn
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Cytokine-induced memory-like NK cells
  • +4 more
  • (no location specified)
Feb 23, 2022

Acute Myeloid Leukemia Trial (TCB008)

Recruiting
  • Acute Myeloid Leukemia
  • Bristol, United Kingdom
  • +5 more
Jan 10, 2023

AML Trial in Hangzhou (CLL1 CAR-T)

Not yet recruiting
  • AML
  • CLL1 CAR-T
  • Hangzhou, China
    The First Affiliated Hospital, Zhejiang University
Jul 17, 2022

Leukemia, Myeloid, Acute Trial (GSK3745417)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • (no location specified)
Jun 15, 2022

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

AML Trial in Hangzhou (CD33 CAR-T)

Not yet recruiting
  • AML
  • CD33 CAR-T
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Jul 21, 2022

Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Suzhou (HYML-122)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia (AML)
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Feb 6, 2022

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

Acute Myeloid Leukemia Trial in Baltimore, Chapel Hill, Charleston (pembrolizumab, Azacitadine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Baltimore, Maryland
  • +2 more
May 19, 2022

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +3 more
Aug 4, 2022

Acute Myeloid Leukemia Trial (Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Gilteritinib 40 MG Oral Tablet
  • +4 more
  • Lexington, Kentucky
    University of Kentucky
Oct 27, 2022

AML Trial in Yanda (CAR-?dT)

Recruiting
  • AML
  • CAR-γδT
  • Yanda, Hebei, China
    Hebei yanda Ludaopei Hospital
Mar 11, 2021

Acute Myeloid Leukemia Trial in Columbus (Universal Donor Natural Killer Cells)

Recruiting
  • Acute Myeloid Leukemia
  • Universal Donor Natural Killer Cells
  • Columbus, Ohio
    Nationwide Children's Hospital
Aug 11, 2022